2025’s biggest life sciences deals show a market in rebound
Version 1 — Brief
Life sciences dealmaking rebounded sharply in 2025, and a PharmaShots ranking produced with DealForma puts three cross-border biopharma partnerships at the top of the list: GSK’s roughly $12.5 billion collaboration with Jiangsu Hengrui Pharmaceuticals, Takeda’s roughly $11.4 billion oncology partnership with Innovent Biologics, and BioNTech’s roughly $11.1 billion strategic alliance with Bristol Myers Squibb. The common thread is clear: large drugmakers spent aggressively on late-stage or platform-rich assets, especially in oncology, immunology, respiratory disease, and obesity, with Chinese biopharma companies playing a much larger role in high-value licensing. DealForma separately reported that global healthcare and life sciences M&A reached about $269.3 billion in announced value across 585 transactions in 2025, nearly double 2024 levels. IPO markets also showed renewed risk appetite: a separate PharmaShots/DealForma roundup said 2025 healthcare IPOs reflected sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare, led by Medline Industries’ $7.2 billion raise, with Caris Life Sciences and Lumexa Imaging also among the biggest offerings. (linkedin.com)
Why it matters: For veterinary professionals, this isn’t a companion-animal deal story, but it is a useful signal about where capital, platform technology, and commercial attention are flowing across the broader health sector. When human biopharma dealmaking accelerates, it can reshape competition for R&D talent, manufacturing capacity, AI-enabled drug discovery tools, and specialty therapeutics that may later influence animal health partnerships, valuations, and investor expectations. The 2025 pattern also suggests buyers favored de-risked, clinically advanced assets over earlier-stage bets, while investors also rewarded scaled platforms, AI-enabled solutions, precision medicine, and revenue-generating healthcare businesses. Large private-capital vehicles were active too: Blackstone closed a $6.3 billion life sciences fund, the largest in its strategy, underscoring how much institutional money is still targeting drugs, medtech, and royalty-based transactions. (dealforma.com)
What to watch: Watch whether this 2025 surge carries into 2026, especially through more cross-border licensing, larger upfront payments, take-private activity such as CVC’s proposed roughly €10.9 billion acquisition of Recordati, and spillover investment into adjacent animal health and veterinary technology markets. (dealforma.com)